NovaBay Pharmaceuticals
Emeryville, US · Delaware corporation · 1 known investors
Founders & leadership
R(
Ramin (Ron) NajafiFounder
MJ
Michael John KazleyChief Executive Officer
TP
Thomas PaulsonExecutive
Board
GM
Gail MaderisBoard director
TA
T. Alex McPhersonBoard director
MR
Massimo RadaelliBoard director
TW
Tony WicksBoard director
MS
Mark SieczkarekBoard director
PE
Paul E. FreimanBoard director
CC
Charles CashionBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$211.2M disclosed across 16 of 19 rounds · 2015–2026
▶$134MraisedJan 2026 · 4 investors · OtherRule 506(b)
▶$134MraisedJan 2026 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michael John KazleyExecutive Officer, Director
- Offering amount
- $134M
- Amount sold
- $134M
- Minimum investment
- $25M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$226KraisedJun 2024 · 5 investors · PharmaceuticalsRule 506(b)
▶$226KraisedJun 2024 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- MIJIA (BOB) WUDirector
- SWAN SITDirector
- PAUL FREIMANDirector
- JULIE GARLIKOVDirector
- JUSTIN HALLExecutive Officer, Director
- TOMMY LAWExecutive Officer
- YENYOU (JEFF) ZHENGDirector
- YONGXIANG (SEAN) ZHENGDirector
- Offering amount
- $226K
- Amount sold
- $226K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$665KraisedApr 2024 · 5 investors · PharmaceuticalsRule 506(b)
▶$665KraisedApr 2024 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- YONGXIANG (SEAN) ZHENGDirector
- TOMMY LAWExecutive Officer
- JUSTIN HALLExecutive Officer
- SWAN SITDirector
- YENYOU (JEFF) ZHENGDirector
- MIJIA (BOB) WUDirector
- PAUL FREIMANDirector
- JULIE GARLIKOVDirector
- Offering amount
- $665K
- Amount sold
- $665K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$554.8KraisedJan 2024 · 5 investors · PharmaceuticalsRule 506(b)
▶$554.8KraisedJan 2024 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JULIE GARLIKOVDirector
- YONGXIANG (SEAN) ZHENGDirector
- YENYOU (JEFF) ZHENGDirector
- PAUL FREIMANDirector
- JUSTIN HALLExecutive Officer, Director
- SWAN SITDirector
- TOMMY LAWExecutive Officer
- MIJIA (BOB) WUDirector
- Offering amount
- $554.8K
- Amount sold
- $554.8K
- Sales commissions
- $44.4K
- Placement agents
- LADENBURG THALMANN & CO, INC.
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMay 2023 · 5 investors · PharmaceuticalsRule 506(b)
▶$3MraisedMay 2023 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JEFFREY KUNINExecutive Officer
- AUDREY KUNINExecutive Officer, Director
- MIJIA (BOB) WUDirector
- JULIE GARLIKOVDirector
- YONGXIANG (SEAN) ZHENGDirector
- SWAN SITDirector
- YENYOU (JEFF) ZHENGDirector
- TOMMY LAWExecutive Officer
- JUSTIN HALLExecutive Officer, Director
- PAUL FREIMANDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Sales commissions
- $240K
- Placement agents
- LADENBURG THALMANN & CO. INC.
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedSep 2022 · 9 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedSep 2022 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- PAUL FREIMANDirector
- YONGXIANG (SEAN) ZHENGDirector
- AUDREY KUNINExecutive Officer, Director
- ANDREW JONESExecutive Officer
- SWAN SITDirector
- JEFFREY KUNINExecutive Officer
- JULIE GARLIKOVDirector
- MIJIA (BOB) WUDirector
- JUSTIN HALLExecutive Officer, Director
- YENYOU (JEFF) ZHENGDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- Sales commissions
- $165.2K
- Placement agents
- LADENBURG THALMANN & CO. INC.
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedSep 2022 · 4 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedSep 2022 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- ANDREW JONESExecutive Officer
- SWAN SITDirector
- PAUL FREIMANDirector
- AUDREY KUNINExecutive Officer, Director
- YENYOU (JEFF) ZHENGDirector
- JULIE GARLIKOVDirector
- JUSTIN HALLExecutive Officer, Director
- YONGXIANG (SEAN) ZHENGDirector
- MIJIA (BOB) WUDirector
- JEFFREY KUNINExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Sales commissions
- $260K
- Placement agents
- LADENBURG THALMANN & CO. INC.
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedNov 2021 · 7 investors · PharmaceuticalsRule 506(b)
▶$15MraisedNov 2021 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- YENYOU (JEFF) ZHENGDirector
- PAUL E. FREIMANDirector
- AUDREY KUNINExecutive Officer
- SWAN SITDirector
- XINZHOU (PAUL) LIDirector
- JEFFREY KUNINExecutive Officer
- MIJIA (BOB) WUDirector
- JUSTIN M. HALLExecutive Officer, Director
- ANDREW JONESExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- Sales commissions
- $1.2M
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who founded NovaBay Pharmaceuticals?
- NovaBay Pharmaceuticals was founded by Ramin (Ron) Najafi.
- Who are NovaBay Pharmaceuticals's investors?
- NovaBay Pharmaceuticals's investors include Framework Ventures.
- How much funding has NovaBay Pharmaceuticals raised?
- NovaBay Pharmaceuticals has disclosed $211.2M raised across 16 of its 19 known rounds.
- Where is NovaBay Pharmaceuticals headquartered?
- NovaBay Pharmaceuticals is headquartered in Emeryville, US.